Skip to content
2000
Volume 23, Issue 4
  • ISSN: 2211-3525
  • E-ISSN: 2211-3533

Abstract

The traditional use of antiseptics, chemotherapeutic, expectorant, mucolytic drugs, and oxygen gas by artificial ventilation does not effectively eliminate hypoxemia in sputum, mucus, pus, and blood asphyxia in COVID-19. The emergency conversion of sputum, mucus, pus, and blood into oxygenated foam inside the airways utilizing the enzyme catalase and warm alkaline hydrogen solutions (WAHPSs) is proposed as a promising area for new therapeutic development. The possibility of physical-chemical repurposing of hydrogen peroxide from an antiseptic in pyolytics, mucolytics, hemolytics, and oxygen-producing antihypoxants by converting a cold, acidic non-carbonated drug into an oxygen-saturated WAHPS and its intrapulmonary injection is pointed out as a way to solve this problem. The possibility of medically enriching blood oxygen in hypoxemia by catalase cleavage of hydrogen peroxide when WAHPSs are administered orally as energy drinks or directly into the blood as injections is pointed out. The fact is that virtually all human tissues are rich in catalase, which immediately breaks down hydrogen peroxide into water and oxygen gas. Inhalation and/or intrapulmonary injections of WAHPSs have been shown to provide intra-airway interaction with catalase in sputum, mucus, pus and/or blood and releases oxygen gas, which foams the biological masses, is absorbed into the blood and eliminates hypoxemia. Thus, the physical-chemical repurposing of known drugs can be considered a promising direction for the discovery of new drugs.

Value of the data:

1) Why are these data useful?

These studies indicate that the enzyme catalase, which is present in many tissues of animals and humans in both normal and disease, can be employed to enrich the tissues with oxygen and eradicate hypoxia when hydrogen peroxide solution is injected into them.

2) Who can benefit from these data?

Mountaineers, divers, submarine sailors, miners, astronauts, traumatologists, resuscitators, cardiologists, transplantologists, pulmonologists, obstetricians and gynecologists, emergency physicians, EMERCOM personnel, and medical workers, providing emergency medical care in cases of smoke in rooms, lack of oxygen in the inhaled air, drowning, bronchial asthma attack, acute respiratory distress syndrome, and asphyxia can use the data presented in this article.

3) How can these data be used/reused for further insights or development of experiments?

These data can be used to develop new antihypoxants, to improve methods of increasing the organism's endurance to hypoxia, methods of organ and tissue preservation, methods of ischemia treatment, methods of emergency medical care in urgent conditions, methods of ARDS treatment and standards of medical care.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/aia/10.2174/0122113525351536241122063840
2024-12-02
2025-08-18

  • From This Site

    /content/journals/aia/10.2174/0122113525351536241122063840
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ShabanovP. SamorodovA. UrakovaN. FisherE. ShchemelevaA. Low fetal resistance to hypoxia as a cause of stillbirth and neonatal encephalopathy.Clin. Exp. Obstet. Gynecol.20245123310.31083/j.ceog5102033
     [Google Scholar]
  2. UrakovA. UrakovaN. ShabanovP. Suffocation in asthma and COVID-19: Supplementation of inhaled corticosteroids with alkaline hydrogen peroxide as an alternative to ECMO.Preprints202310.20944/preprints202307.0627.v1
     [Google Scholar]
  3. UrakovA.L. ShabanovP.D. Acute respiratory syndrome-2 (SARS-CoV-2): A solution of hydrogen peroxide and sodium bicarbonate as an expectorant for recanalization of the respiratory tract and blood oxygenation in respiratory obstruction (review).Rev. Clin. Pharmacol. Drug Ther.2021194383393[review].10.17816/RCF194383‑393
     [Google Scholar]
  4. Oude Lansink-HartgringA. van MinnenO. VermeulenK.M. van den BerghW.M. Oude Lansink-HartgringA. van den BerghW.M. VermeulenK.M. Dos Reis MirandaD. DelnoijT.S.R. Elzo KraemerC.V. MaasJ.J. VlaarA.P.J. DonkerD.W. ScholtenE. BalzereitA. van den BruleJ. KuijpersM. Hospital costs of extracorporeal membrane oxygenation in adults: A systematic review.PharmacoEconom. Open20215461362310.1007/s41669‑021‑00272‑9 34060061
     [Google Scholar]
  5. FisherE.L. UrakovA.L. SamorodovA.V. BashirovI.I. ShabanovP.D. Alkaline hydrogen peroxide solutions: Expectorant, pyolytic, mucolytic, haemolytic, oxygen-releasing, and decolorizing effects.Rev. Clin. Pharmacol. Drug Ther.202321213515010.17816/RCF492316
     [Google Scholar]
  6. KatoT. AsakuraT. EdwardsC.E. DangH. MikamiY. OkudaK. ChenG. SunL. GilmoreR.C. HawkinsP. De la CruzG. CooleyM.R. BaileyA.B. HewittS.M. ChertowD.S. BorczukA.C. SalvatoreS. MartinezF.J. ThorneL.B. AskinF.B. EhreC. RandellS.H. O’NealW.K. BaricR.S. BoucherR.C. Prevalence and mechanisms of mucus accumulation in COVID-19 lung disease.Am. J. Respir. Crit. Care Med.2022206111336135210.1164/rccm.202111‑2606OC 35816430
     [Google Scholar]
  7. UrakovA.L. UrakovaN.A. AgarvalR.K. Method of maintenance of live fish during transportation and storage.RU Patent 2563151C22015
  8. UrakovA.L. UrakovaN.A. ReshetnikovA.P. SoikherM.G. SoikherE.M. KopylovM.V. ChernovaL.V. E.M.Soikher's hyperoxygenated agent for venous oxygen saturation.RU Patent 2538662C12015
  9. UrakovA.L. UrakovaN.A. NikitjukD.B. Agent for increasing resistance to hypoxia RU2604129C2 RUPatent 2604129C22016
  10. UrakovA.L. Energy drinkRU Patent 2639493C12017
  11. UrakovA.L. Means for physical endurance increase.RU Patent 2634271C12017
  12. UrakovA.L. Lympho-subsitute for local maintaining viability of organs and tissues in hypoxia and ischemia.RU Patent 2586292C12016
  13. UrakovA. UrakovaN. NikolenkoV. BelkharoevaR. AchkasovE. KochurovaE. GavryushovaL. SinelnikovM. Current and emerging methods for treatment of hemoglobin related cutaneous discoloration: A literature review.Heliyon202171e0595410.1016/j.heliyon.2021.e05954 33506129
     [Google Scholar]
  14. UrakovA.L. The change of physical-chemical factors of the local interaction with the human body as the basis for the creation of materials with new properties. Építőanyag.JSBCM2015671210.14382/epitoanyag‑jsbcm.2015.1
     [Google Scholar]
  15. UrakovaN.A. Temperature, osmotic and acidic activity of infusion solutions as an integral part of their mechanism of action.Rev. Clin. Pharm. Drug Ther.202119217518210.17816/RCF192175‑182
     [Google Scholar]
  16. UrakovA. UrakovaN. SamorodovA. ShabanovP. YagudinI. StolyarenkoA. SuntsovaD. MuhutdinovN. Thermal imaging of local skin temperature as part of quality and safety assessment of injectable drugs.Heliyon2023101e2341710.1016/j.heliyon.2023.e23417
     [Google Scholar]
  17. StrelkovN.S. UrakovA.L. KorovyakovA.P. UrakovaN.A. Method for treating long-term non-healing wounds.RU Patent 2187287C12002
  18. UrakovaN.A. UrakovA.L. UrakovaN.V. GadelshinaA.A. Bleaching opener of dried blood for wrapping bandages adhered to a wound.RU Patent 2653465C12018
  19. UrakovA.L. ShabanovP.D. GurevichK.G. LovtsovaL.V. Supplementing traditional drug formulation with the “needed” gases opens the way for the development of a new generation of drugs.Psychopharmacol. biol. narcol.202314151410.17816/phbn321616
     [Google Scholar]
  20. UrakovA.L. UrakovaN.A. YagudinI.I. SvetovaM.D. SuntsovaD.O. COVID-19: Artificial sputum, respiratory obstruction method and screening of pyolitic and antihypoxic drugs.Bioimpacts202212439339410.34172/bi.2022.23877 35975207
     [Google Scholar]
  21. UrakovA. UrakovaN. ReshetnikovA. Oxygen alkaline dental’s cleaners from tooth plaque, food debris, stains of blood, and pus: A narrative review of the history of inventions.J. Int. Soc. Prev. Community Dent.20199542743310.4103/jispcd.JISPCD_296_19 31620374
     [Google Scholar]
  22. UrakovA.L. Pus solvents as new drugs with unique physical and chemical properti.Rev. Clin. Pharmacol. Drug Ther.2020174899510.17816/RCF17489‑95
     [Google Scholar]
  23. SamylinaI.A. AlesM.Y. UrakovA.L. Aerosol for inhalations in obstructive bronchitis.RU Patent 2735502C12020
  24. UrakovA.L. UrakovaN.A. Aerosol for invasive mechanical ventilation in COVID-19.RU Patent 2742505C12021
  25. UrakovA.L. UrakovaN.A. ShabanovP.D. Warm alkaline hydrogen peroxide solution for intrapulmonary injection.RU Patent 2807851C12023
  26. PushpakomS. IorioF. EyersP.A. EscottK.J. HopperS. WellsA. DoigA. GuilliamsT. LatimerJ. McNameeC. NorrisA. SanseauP. CavallaD. PirmohamedM. Drug repurposing: Progress, challenges and recommendations.Nat. Rev. Drug Discov.2019181415810.1038/nrd.2018.168 30310233
     [Google Scholar]
  27. UrakovA. UrakovaN. FisherE. ShchemelevaA. StolyarenkoA. MartiushevaV. ZavarzinaM. Antiseptic pyolytics and warming wet compresses improve the prospect of healing chronic wounds.Explor. Med.2023474775410.37349/emed.2023.00175
     [Google Scholar]
  28. HughesA.N. LiX. LehmanJ.S. DiCaudoD.J. MudappathiR. HwangA. KechterJ. PittelkowM.R. MangoldA.R. SekulicA. Drug repurposing using molecular network analysis identifies jak as targetable driver in necrobiosis lipoidica.JID Innov.20244610029610.1016/j.xjidi.2024.100296
     [Google Scholar]
  29. UrakovA.L. UrakovaN.A. ReshetnikovA.P. ShabanovP.D. WangY. BodduluriP.V. SamorodovA.V. RozovR.A. ShchemelevaA.A. NovikovV.E. PozhilovaE.V. Pyolytics as a product of the physical–chemical repurposing of antiseptics and an alternative to larval therapy for chronic wounds.Rev. Clin. Pharmacol. Drug Ther.202421428729710.17816/RCF606648
     [Google Scholar]
  30. MagP. Nemes-TerényiM. JerzseleÁ. MátyusP. Some aspects and convergence of human and veterinary drug repositioning.Molecules20242918447510.3390/molecules29184475 39339469
     [Google Scholar]
  31. UrakovA. UrakovaN. SorokinaY. SamorodovA.V. FisherE. Targeted modification of physical-chemical properties of drugs as a universal way to transform “old” drugs into “new” drugs.Drug Repurposing - Advances, Scopes and Opportunities in Drug Discovery. RudrapalM. IntechOpen202310.5772/intechopen.110480
     [Google Scholar]
  32. BanerjeeJ. TiwariA.K. BanerjeeS. Drug repurposing for cancer.Prog. Mol. Biol. Transl. Sci.202420712315010.1016/bs.pmbts.2024.03.032 38942535
     [Google Scholar]
  33. MorrisR. AliR. ChengF. Drug repurposing using FDA adverse event reporting system (FAERS) database.Curr. Drug Targets202425745446410.2174/0113894501290296240327081624 38566381
     [Google Scholar]
  34. SatishK.S. SaraswathyG.R. RiteshG. SaravananK.S. KrishnanA. BhargavaJ. UshnaaK. DsouzaP.L. Exploring cutting-edge strategies for drug repurposing in female cancers – An insight into the tools of the trade.Prog. Mol. Biol. Transl. Sci.202420735541510.1016/bs.pmbts.2024.05.002 38942544
     [Google Scholar]
  35. UrakovA. UrakovaN. ReshetnikovA. ShklyaevA. NikolenkoV. OsipovA. KlyachkoN. SorokinaY. MuhutdinovN. OkovityiS. ShabanovP. Catalase: A potential pharmacologic target for hydrogen peroxide in the treatment of COVID-19.Curr. Top. Med. Chem.202424252191221010.2174/0115680266322046240819053909 39253918
     [Google Scholar]
/content/journals/aia/10.2174/0122113525351536241122063840
Loading
Pharmacological Activities of Warm Alkaline Hydrogen Peroxide Solution and Therapeutic Potential in Medicine: Physical-Chemical Reprofiling as a Promising Lead for Drug Discovery
Anti Infect. Agents 23, E22113525351536 (2025); https://doi.org/10.2174/0122113525351536241122063840
/content/journals/aia/10.2174/0122113525351536241122063840
/content/journals/aia/10.2174/0122113525351536241122063840
Loading

Data & Media loading...


  • Article Type:     Editorial
Keyword(s): antihypoxants; Antiseptics; ARDS; coronavirus; hypoxia; pyolytics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test